These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27001049)

  • 21. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
    Marchini A; Scott EM; Rommelaere J
    Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
    Workenhe ST; Verschoor ML; Mossman KL
    Future Oncol; 2015; 11(4):675-89. PubMed ID: 25686121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Oncolytic enteroviruses].
    Chumakov PM; Morozova VV; Babkin IV; Baĭkov IK; Netesov SV; Tikunova NV
    Mol Biol (Mosk); 2012; 46(5):712-25. PubMed ID: 23156670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses.
    Bucurescu S
    Acta Pharm; 2010 Dec; 60(4):407-13. PubMed ID: 21169133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor Models.
    Yumul R; Richter M; Lu ZZ; Saydaminova K; Wang H; Wang CH; Carter D; Lieber A
    Hum Gene Ther; 2016 Apr; 27(4):325-37. PubMed ID: 26993072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Directing systemic oncolytic viral delivery to tumors via carrier cells.
    Nakashima H; Kaur B; Chiocca EA
    Cytokine Growth Factor Rev; 2010; 21(2-3):119-26. PubMed ID: 20226717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer scene investigation: how a cold virus became a tumor killer.
    Post DE; Shim H; Toussaint-Smith E; Van Meir EG
    Future Oncol; 2005 Apr; 1(2):247-58. PubMed ID: 16555996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
    Guse K; Dias JD; Bauerschmitz GJ; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Jun; 14(11):902-11. PubMed ID: 17377596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining oncolytic virotherapy and tumour vaccination.
    Bridle BW; Hanson S; Lichty BD
    Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mounting a strategic offense: fighting tumor vasculature with oncolytic viruses.
    Angarita FA; Acuna SA; Ottolino-Perry K; Zerhouni S; McCart JA
    Trends Mol Med; 2013 Jun; 19(6):378-92. PubMed ID: 23540715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
    Rajani KR; Vile RG
    Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Replication-selective oncolytic viruses in the treatment of cancer.
    Everts B; van der Poel HG
    Cancer Gene Ther; 2005 Feb; 12(2):141-61. PubMed ID: 15472714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Objective determination of the oncolytic potency of conditionally-replicating adenoviruses using mathematical modeling.
    Idema S; Dirven CM; van Beusechem VW; Carette JE; Planqué R; Noske DP; Lamfers ML; Vandertop WP
    J Gene Med; 2010 Jul; 12(7):564-71. PubMed ID: 20603863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Newcastle disease virus: a promising agent for tumour immunotherapy.
    Zhao L; Liu H
    Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Model-based rational design of an oncolytic virus with improved therapeutic potential.
    Le Bœuf F; Batenchuk C; Vähä-Koskela M; Breton S; Roy D; Lemay C; Cox J; Abdelbary H; Falls T; Waghray G; Atkins H; Stojdl D; Diallo JS; Kærn M; Bell JC
    Nat Commun; 2013; 4():1974. PubMed ID: 23764612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mathematical and Computational Modeling for Tumor Virotherapy with Mediated Immunity.
    Timalsina A; Tian JP; Wang J
    Bull Math Biol; 2017 Aug; 79(8):1736-1758. PubMed ID: 28593497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A mathematical model for cell cycle-specific cancer virotherapy.
    Crivelli JJ; Földes J; Kim PS; Wares JR
    J Biol Dyn; 2012; 6 Suppl 1():104-20. PubMed ID: 22873678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Models of Virus-Induced Carcinogenesis and Oncolytic Viruses.
    Lairmore MD; Niewiesk S
    ILAR J; 2016; 57(1):1-2. PubMed ID: 27034389
    [No Abstract]   [Full Text] [Related]  

  • 39. Design of virotherapy for effective tumor treatment.
    Garcia-Aragoncillo E; Hernandez-Alcoceba R
    Curr Opin Mol Ther; 2010 Aug; 12(4):403-11. PubMed ID: 20677091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncolytic Viruses: Therapeutics With an Identity Crisis.
    Breitbach CJ; Lichty BD; Bell JC
    EBioMedicine; 2016 Jul; 9():31-36. PubMed ID: 27407036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.